Optic neuropathy

Neurology

Volumn 46, Issue 2, 1996, Pages 315-322

  Newman, Nancy J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOSOMAL RECESSIVE DISORDER; CHROMOSOMAL LOCALIZATION; EYE TOXICITY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; OPTIC NERVE DISEASE; OPTIC NERVE LESION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VISION;

EID: 0029897737     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.2.315     Document Type: Review

References (144)

1. Hayreh SS. Anterior ischemic optic neuropathy. New York: Springer Verlag, 1975.
2. Hayreh SS. Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management. Eye 1990;4:25-41.
3. Hayreh SS. Anterior ischemic optic neuropathy. Arch Neurol 1981;38:675-678.
4. Moro F, Doro D, Mantovani E. Anterior ischemic optic neuropathy and aging. Metab Pediatr Syst Ophthalmol 1989;12: 46-57.
5. Mack HG, O'Day J, Currie JN. J Clin Neuroophthalmol 1991; 11:221-227.
6. Siatkowski RM, Gass JD, Glaser JS, Smith JL, Schatz NJ, Schiffman J. Fluorescein angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol 1993;115:57-63.
7. Rosenfeld SI, Kosmorsky GS, Klingele TG, Burde RM, Cohn EM. Treatment of temporal arteritis with ocular involvement. Am J Med 1986;80:143-145.
8. Matzkin DC, Slamovits TL, Sachs R, Burde RM. Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant-cell arteritis. Ophthalmology 1992;99:68-71.
9. Postel EA, Pollock SC. Recovery of vision in a 47-year-old man with fulminant giant cell arteritis. J Clin Neuroophthalmol 1993;13:262-270.
10. Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology 1994;101:1779-1785.
11. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994;120:987-992.
12. Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994;118:766-780.
13. The IONDT Study Group. The clinical profile of nonarteritic anterior ischemic optic neuropathy: Experience of the ischemic optic neuropathy decompression trial. Arch Opthalmol (in press).
14. Ellenberger C Jr, Keltner JL, Burde RM. Acute optic neuropathy in older patients. Arch Neurol 1973;28:182-185.
15. Eagling EM, Sanders MD, Miller SJH. Ischaemic papillopathy: clinical and fluorescein angiographic review of forty cases. Br J Ophthalmol 1974;58:990-1008.
16. Boghen DR, Glaser JS. Ischemic optic neuropathy: the clinical profile and history. Brain 1975;98:689-708.
17. Repka MX, Savino PJ, Schatz NJ, Sergott RC. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 1983;96:478-483.
18. Sawle GV, James CB, Ross Russell RW. The natural history of non-arteritic anterior ischaemic optic neuropathy. J Neurol Neurosurg Psychiatry 1990;53:830-833.
19. Hayreh SS, Podhajsky P. Visual field defects in anterior ischemic optic neuropathy. Docum Ophthal Proc Series 1979; 19:53-71.
20. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol 1991; 109:1668-1672.
21. Arnold AC, Hepler RS. Natural history of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 1994;14: 66-69.
22. Beri M, Klugman MR, Kohler JA, Hayreh SS. Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors. Ophthalmology 1987;94:1020-1028.
23. Guyer DR, Miller NR, Auer CL, Fine SL. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol 1985;103:1136-1142.
24. Fry CL, Carter JE, Kanter MC, Tegeler CH, Tuley MR. Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke 1993;24:539-542.
25. Lieberman MF, Shahi A, Green WR. Embolic ischemic optic neuropathy. Am J Ophthalmol 1978;86:206-210.
26. Portnoy SL, Beer PM, Packer AJ, Van Dyk HJL. Embolic anterior ischemic optic neuropathy. J Clin Neuroophthalmol 1989;9:21-25.
27. Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 1987;94:1503-1508.
28. Sergott RC, Cohen MS, Bosley TM, Savino PJ. Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol 1989; 107:1743-1754.
29. Kelman SE, Elman MJ. Optic nerve sheath decompression for non-arteritic ischemic optic neuropathy improves multiple visual function parameters. Arch Ophthalmol 1991;109: 667-671.
30. Spoor TC, Wilkinson MJ, Ramocki JM. Optic nerve sheath decompression for the treatment of progressive nonarteritic ischemic optic neuropathy. Am J Ophthalmol 1991;111:724-728.
31. Spoor TC, McHenry JG, Lau-Sickon L. Progressive and static nonarteritic ischemic optic neuropathy treated by optic nerve sheath decompression. Ophthalmology 1993;100:306-311.
32. Jablons MM, Glaser JS, Schatz NJ, Siatkowski RM, Tse DT, Kronish JW. Optic nerve sheath fenestration for treatment of progressive ischemic optic neuropathy. Results in 26 patients. Arch Ophthalmol 1993;111:84-87.
33. Glaser JS, Teimory M, Schatz NJ. Optic nerve sheath fenestration for progressive ischemic optic neuropathy. Results in second series consisting of 21 eyes. Arch Ophthalmol 1994; 112:1047-1050.
34. Kelman SE. The Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1993;111:1616-1618.
35. Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful: results of the Ischemic Optic Neuropathy Decompression Trial. JAMA 1995;273:625-632.
36. Beck RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol 1988;106:1051-1053.
37. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991;109:1673-1678.
38. Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual field profile of optic neuritis. The experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1993;111:231-234.
39. Beck RW, Kupersmith MJ, Cleary PA, et al. Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1993; 100:691-698.
40. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-588.
41. Beck RW, Cleary PA, Optic Neuritis Study Group. Optic Neuritis Treatment Trial. One-year follow-up results. Arch Ophthalmol 1993;111:773-775.
42. Beck RW, Optic Neuritis Study Group. Corticosteroid treatment of optic neuritis: a need to change treatment practices. Neurology 1992;42:1133-1135.
43. Keltner JL, Johnson CA, Spurr JO, et al. Visual field profile of optic neuritis: one-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol 1994;112:946-953.
44. Beck RW, Cleary PA, Backlund JC, et al. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994;101:1771-1778.
45. Chrousos GA, Kattah JC, Beck RW, et al. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993;269:2110-2112.
46. Beck RW, Arlington J, Murtagh R, et al. Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group. Arch Neurol 1993;50:841-846.
47. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769.
48. Beck RW, Optic Neuritis Study Group. The Optic Neuritis Treatment Trial: three-year follow-up results. Arch Ophthalmol 1995;113:136-137.
49. Lessell S. Nutritional disorders. Ophthalmological aspects. Bull Soc Belge Ophthalmol 1983;208-I:469-472.
50. Carroll FD. The etiology and treatment of tobacco-alcohol amblyopia. Parts I and II. Am J Ophthalmol 1944;27:713-725, 847-863.
51. Potts AM. Tobacco amblyopia. Surv Ophthalmol 1973;17: 313-339.
52. Harrington DO. Amblyopia due to tobacco, alcohol and nutritional deficiency. Am J Ophthalmol 1962;53:967-972.
53. Kumar A, Sandramouli S, Verma L, Tewari HK, Khosla PK. Ocular ethambutol toxicity: is it reversible? J Clin Neuroophthalmol 1993;13:15-17.
54. Rizzo JF III, Lessell S. Tobacco amblyopia. Am J Ophthalmol 1993;116:84-87.
55. Dang CV. Tobacco-alcohol amblyopia: a proposed biochemical basis for pathogenesis. Med Hypotheses 1981;7:1317-1328.
56. 12 deficiency. Lancet 1958;2:286-290.
57. Schepens CL. Is tobacco amblyopia a deficiency disease? Trans Ophthalmol Soc UK 1946;66:309-331.
58. Wilson J. Cyanide in human disease: a review of clinical and laboratory evidence. Fundam Appl Toxicol 1983;3:397-399.
59. Chisholm IA, Pettigrew AR. Biochemical observations in toxic optic neuropathy. Trans Ophthalmol Soc UK 1970;90: 827-838.
60. Jestico JV, O'Brien MD, Teoh R, Toseland PA, Wong HC. Whole blood cyanide levels in patients with tobacco amblyopia. J Neurol Neurosurg Psychiatry 1984;47:573-578.
61. Costagliola C, Cotticelli L, Menzione M, Rinaldi M, Russo S, Rinaldi E. Red cell reduced glutathione and tobacco smoke-induced optic neuropathy. Metab Pediatr Syst Ophthalmol 1990;13:96-98.
62. 12. Am J Clin Nutr 1994;60:559-566.
63. Lannan S, Donaldson K, Brown D, MacNee W. Effect of cigarette smoke and its condensates on alveolar epithelial injury in vitro. Am J Physiol 1994;266:L92-100.
64. Tsuchiya M, Suzuki YJ, Cross CE, Packer L. Superoxide generated by cigarette smoke damages the respiratory burst and induces physical changes in the membrane order and water organization of inflammatory cells. Ann N Y Acad Sci 1993;686:39-52.
65. 12 deficiency in monkeys. Neurology 1976;26:905-914.
66. 12-deficient monkeys. Trans Ophthalmol Soc UK 1970;90:839-846.
67. Hamilton HE, Ellis PP, Sheets RF. Visual impairment due to optic neuropathy in pernicious anemia: report of a case and review of the literature. Blood 1959;14:378-385.
68. Troncoso J, Mancall EL, Schatz NJ. Visual evoked potentials in pernicious anemia. Arch Neurol 1979;36:168-169.
69. Dreyfus PM. Blood transketolase levels in tobacco-alcohol amblyopia. Arch Ophthalmol 1965;74:617-620.
70. Rodger FC. Experimental thiamin deficiency as a cause of degeneration in the visual pathway of the rat. Br J Ophthalmol 1953;37:11-29.
71. Golnik KC, Schaible ER. Folate-responsive optic neuropathy. J Neuroophthalmol 1994;14:163-169.
72. 12, and other vitamins. Retina 1982;2:288-293.
73. Denny-Brown DE. Neurological conditions resulting from prolonged and severe dietary restriction. Medicine 1947;26: 41-113.
74. Fisher CM. Residual neuropathological changes in Canadians held prisoners of war by the Japanese (Strachan's disease). Can Serv Med J 1955;11:157-199.
75. King JH Jr, Passmore JW. Nutritional amblyopia. A study of American prisoners of war in Korea. Am J Ophthalmol 1955; 39(suppl):173-186.
76. Spillane JD. Nutritional disorders of the nervous system. Edinburgh: E & S Livingsone, 1947.
77. Ridley H. Ocular disturbances associated with malnutrition. Trans Ophthalmol Soc UK 1946;66:45-71.
78. Cuban National Operative Group on Epidemic Neuropathy. Epidemic neuropathy in Cuba. Cuban Ministry of Public Health, Havana, Cuba, July 30, 1993.
79. Llanos G, Asher D, Brown P, et al. Epidemic neuropathy in Cuba. Epidemiol Bull 1993;14:1-4.
80. Lincoff NS, Odel JG, Hirano M. 'Outbreak' of optic and peripheral neuropathy in Cuba? JAMA 1993;270:511-518.
81. CDC. Epidemic neuropathy - Cuba, 1991-1994. MMWR 1994;43:183-192.
82. Roman GC. An epidemic in Cuba of optic neuropathy, sensorineural deafness, peripheral sensory neuropathy and dorsolateral myeloneuropathy. J Neurol Sci 1994;127:11-28.
83. Sadun AA, Martone JF, Muci-Mendoza R, et al. Epidemic optic neuropathy in Cuba. Eye findings. Arch Ophthalmol 1994;112:691-699.
84. Roman GC. Epidemic optic neuropathy in Cuba: a plea to end the United States economic embargo on a humanitarian basis. Neurology 1994;44:1784-1786.
85. Cuba Neuropathy Field Investigation Team. Epidemic optic neuropathy in Cuba: clinical characterization and risk factors. N Engl J Med 1995;333:1176-1182.
86. Madan D. Nota sobre una forma sensitiva de neuritis periferica, ambliopia por neuritis optica retrobulbar. Cron Med Quirurg Habana 1898;24:81-86.
87. Santos Fernandez J. Ambliopia por neuritis periferica debida a autointoxicacion de origen intestinal por alimentacion defectuosa. Cron Med Quirurg Habana 1900;26:330-334.
88. Hedges TR III, Sokol S, Tucker K. Optic and peripheral neuropathy in Cuba [letter]. JAMA 1994;271:662-663.
89. Hirano M, Odel JG, Lincoff NS. Optic and peripheral neuropathy in Cuba [letter]. JAMA 1994;271:663.
90. Sadun AA, Martone JF, Reyes L, DuBois L, Roman GC, Caballero B. Optic and peripheral neuropathy in Cuba [letter]. JAMA 1994;271:663-664.
91. Hirano M, Cleary JM, Stewart AM, et al. Mitochondrial DNA mutations in an outbreak of optic neuropathy in Cuba. Neurology 1994;44:843-845.
92. Newman NJ, Torroni A, Brown MD, et al. Epidemic optic neuropathy in Cuba not associated with mitochondrial DNA mutations found in Leber's hereditary optic neuropathy patients. Am J Ophthalmol 1994;118:158-168.
93. Rizzo JF III. Adenosine triphosphate deficiency: a genre of optic neuropathy. Neurology 1995;45:11-16.
94. Cullom ME, Heher KL, Miller NR, Savino PJ, Johns DR. Leber's hereditary optic neuropathy masquerading as tobacco-alcohol amblyopia. Arch Ophthalmol 1993;111:1482-1485.
95. Johns DR, Neufeld MJ, Hedges TR III. Mitochondrial DNA mutations in Cuban optic and peripheral neuropathy. J Neuroophthalmol 1994;14:135-140.
96. Newman NJ, Torroni A, Brown MD, et al. Cuban optic neuropathy [letter]. Neurology 1995;45:397.
97. Torroni A, Brown MD, Lott MT, et al. African, Native American, and European mitochondrial DNAs in Cubans from Pinar del Rio province and implications for the recent epidemic neuropathy in Cuba. Hum Mutat 1995;5:310-317.
98. Newman NJ. Leber's hereditary optic neuropathy. New genetic considerations. Arch Neurol 1993;50:540-548.
99. van Senus AHC. Leber's disease in the Netherlands. Doc Ophthalmol 1963;17:1-163.
100. Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol 1991;111:750-762.
101. Smith JL, Hoyt WF, Susac JO. Ocular fundus in acute Leber optic neuropathy. Arch Ophthalmol 1973;90:349-354.
102. Nikoskelainen E, Hoyt WF, Nummelin K. Ophthalmoscopic findings in Leber's hereditary optic neuropathy. II. The fundus findings in the affected family members. Arch Ophthalmol 1983;101:1059-1068.
103. Ortiz RG, Newman NJ, Manoukian S, Diesenhouse MC, Lott MT, Wallace DC. Optic disk cupping and electrocardiographic abnormalities in an American pedigree with Leber's hereditary optic neuropathy. Am J Ophthalmol 1992;113: 561-566.
104. Nikoskelainen E, Wanne O, Dahl M. Pre-excitation syndrome and Leber's hereditary optic neuroretinopathy. Lancet 1985;1:696.
105. Bower SPC, Hawley I, Mackey DA. Cardiac arrhythmia and Leber's hereditary optic neuropathy. Lancet 1992;339:1427-1428.
106. Nikoskelainen EK, Savontaus M-L, Huoponen K, Antila K, Hartiala J. Pre-excitation syndrome in Leber's hereditary optic neuropathy. Lancet 1994;344:857-858.
107. De Weerdt CJ, Went LN. Neurological studies in families with Leber's optic atrophy. Acta Neurol Scand 1971;47:541-554.
108. Palan A, Stehouwer A, Went LN. Studies on Leber's optic neuropathy III. Doc Ophthalmol 1989;71:77-87.
109. Lees F, MacDonald A-ME, Aldren Turner JW. Leber's disease with symptoms resembling disseminated sclerosis. J Neurol Neurosurg Psychiatry 1964;27:415-421.
110. Harding AE, Sweeney MG, Miller DM, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992;115:979-989.
111. Flanigan KM, Johns DR. Association of the 11778 mitochondrial DNA mutation and demyelinating disease. Neurology 1993;43:2720-2722.
112. Kellar-Wood H, Robertson N, Govan GG, Compston DAS, Harding AE. Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Ann Neurol 1994; 36:109-112.
113. Novotny EJ, Singh G, Wallace DC, et al. Leber's disease and dystonia: a mitochondrial disease. Neurology 1986;36:1053-1060.
114. Marsden CD, Lang AE, Quinn NP, et al. Familial dystonia and visual failure with striatal CT lucencies. J Neurol Neurosurg Psychiatry 1986;49:500-509.
115. Bruyn GW, Vielvoye GJ, Went LN. Hereditary spastic dystonia: a new mitochondrial encephalopathy? Putaminal necrosis as a diagnostic sign. J Neurol Sci 1991;103:195-202.
116. Leuzzi V, Bertini E, De Negri AM, et al. Bilateral striatal necrosis, dystonia and optic atrophy in two siblings. J Neurol Neurosurg Psychiatry 1992;55:16-19.
117. Wallace DC. A new manifestation of Leber's disease and a new explanation for the agent responsible for its unusual pattern of inheritance. Brain 1970;93:121-132.
118. Brown MD, Wallace DC. Spectrum of mitochondrial DNA mutations in Leber's hereditary optic neuropathy. Clin Neurosci 1994;2:138-145.
119. Johns DR, Neufeld MJ. Cytochrome c oxidase mutations in Leber hereditary optic neuropathy. Biochem Biophys Res Commun 1993;196:810-815.
120. Johns DR, Neufeld MJ. Cytochrome b mutations in Leber hereditary optic neuropathy. Biochem Biophys Res Commun 1991;181:1358-1364.
121. Brown MD, Voljavec AS, Lett MT, Torroni A, Yang C-C, Wallace DC. Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics 1992;130:163-173.
122. Huoponen K, Vilkki J, Aula P, Nikoskelainen EK, Savontaus ML. A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. Am J Hum Genet 1991;48: 1147-1153.
123. Johns DR, Berman J. Alternative, simultaneous complex I mitochondrial DNA mutations in Leber's hereditary optic neuropathy. Biochem Biophys Res Commun 1991;174:1324-1330.
124. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988;242:1427-1430.
125. Howell N, Bindoff LA, McCullough DA, et al. Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. Am J Hum Genet 1991; 49:939-950.
126. Brown MD, Voljavec AS, Lott MT, MacDonald I, Wallace DC. Leber's hereditary optic neuropathy: a model for mitochondrial neurodegenerative diseases. FASEB J 1992;6:2791-2799.
127. Johns DR, Neufeld MJ, Park RD. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem Biophys Res Commun 1992;187:1551-1557.
128. Mackey DA. Three subgroups of patients from the United Kingdom with Leber hereditary optic neuropathy. Eye 1994; 8:431-436.
129. Johns DR, Heher KL, Miller NR, Smith KH. Leber's hereditary optic neuropathy. Clinical manifestations of the 14484 mutation. Arch Ophthalmol 1993;111:495-498.
130. Obermaier-Kusser B, Lorenz B, Schubring S, et al. Features of mtDNA mutation patterns in European pedigrees and sporadic cases with Leber hereditary optic neuropathy. Am J Hum Genet 1994;55:1063-1066.
131. Oostra RJ, Bolhuis PA, Wijburg FA, Zorn-Ende G, Bleeker-Wagemakers EM. Leber's hereditary optic neuropathy. Correlations between mitochondrial genotype and visual outcome. J Med Genet 1994;31:280-286.
132. Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, Da Costa J, Harding AE. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 1995;118:319-337.
133. Howell N, Kubacka I, Xu M, McCullough DA. Leber hereditary optic neuropathy: involvement of the mitochondrial ND1 gene and evidence for an intragenic suppressor mutation. Am J Hum Genet 1991;48:935-942.
134. Jun AS, Brown MD, Wallace DC. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc Natl Acad Sci USA 1994;91:6206-6210.
135. Weiner NC, Newman NJ, Lessell S, Johns DR, Lott MT, Wallace DC. Atypical Leber's hereditary optic neuropathy with molecular confirmation. Arch Neurol 1993;50:470-473.
136. Hoyt CS. Autosomal dominant optic atrophy: a spectrum of disability. Ophthalmology 1980;87:245-251.
137. Kline LB, Glaser JS. Dominant optic atrophy: the clinical profile. Arch Ophthalmol 1979;97:1680-1686.
138. Eiberg H, Kjer B, Kjer P, Rosenberg T. Dominant optic atrophy (OPA1) mapped to chromosome 3q region. 1. linkage analysis. Hum Mol Genet 1994;3:977-980.
139. Newman NJ. Hereditary optic neuropathies. In: Newman SA, Tusa RJ, eds. Neuro-ophthalmological disorders. Diagnostic work-up and management. New York: Marcel Dekker, 1995:143-151.
140. Lessell S, Rosman NP. Juvenile diabetes mellitus and optic atrophy. Arch Neurol 1977;34:759-765.
141. Bu X, Rotter JI. Wolfram syndrome: a mitochondrial-mediated disorder? Lancet 1993;342:598-600.
142. Bundey S, Pulton K, Whitwell H, Curtis E, Brown IAR, Fielder AR. Mitochondrial abnormalities in the DIDMOAD syndrome. J Inherit Metab Dis 1992;15:315-319.
143. Rötig A, Cormier V, Chatelain P, et al. Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, optic atrophy, and deafness (Wolfram syndrome, MIM 222300). J Clin Invest 1993;91:1095-1098.
144. Polymeropoulos MH, Swift RG, Swift M. Linkage of the gene for Wolfram syndrome to markers on the short arm of chromosome 4. Nature Genetics 1994;8:95-97.